Every Cure

Every Cure

Biotechnology

Philadelphia, PA 6,484 followers

Every Cure is leveraging AI to unlock the full potential of every drug to treat every disease it possibly can.

About us

Every Cure is a nonprofit organization dedicated to unlocking the full potential of every existing medicine to treat every disease possible. Repurposing existing drugs is the fastest and most efficient way to treat diseases with the greatest return on investment for saving lives. However, systemic barriers impede repurposing, so patients suffer while potential treatments are not fully utilized. Every Cure overcomes these barriers to systematically identify and advance promising repurposing opportunities and save lives. Every Cure is taking a revolutionary and disruptive approach to overcome these systemic barriers by developing a comprehensive, open-source data engine to generate predictive efficacy scores for all 3,000 drugs against all 12,000 diseases and rapidly advance treatments to patients. In partnership with academia, industry, and government, Every Cure is integrating proprietary and public data into a comprehensive dataset, optimizing AI ranking algorithms, validating the most promising drug-disease matches, performing trials, and ensuring patient access to effective therapies.

Website
EveryCure.org
Industry
Biotechnology
Company size
11-50 employees
Headquarters
Philadelphia, PA
Type
Nonprofit
Founded
2022
Specialties
biotechnology, artificial intelligence, drug development, drug repurposing, non-profit, medicine, and medtech

Locations

Employees at Every Cure

Updates

  • View organization page for Every Cure, graphic

    6,484 followers

    Every Cure to Receive $48.3M from Advanced Research Projects Agency for Health (ARPA-H) to Develop AI-Driven Platform to Revolutionize Future of Drug Development and Repurposing ARPA-H contract will supercharge Every Cure’s work to identify existing medicines that can be repurposed to treat currently untreated diseases. Initial progress utilizing a pilot version of the AI platform and stakeholder engagement has led to the identification of potential treatments for sickle cell disease, ALS, and autism spectrum disorder. https://lnkd.in/d6wVWutU

    Every Cure to Receive $48.3M from ARPA-H to Develop AI-Driven Platform to Revolutionize Future of Drug Development and Repurposing

    Every Cure to Receive $48.3M from ARPA-H to Develop AI-Driven Platform to Revolutionize Future of Drug Development and Repurposing

    https://everycure.org

  • View organization page for Every Cure, graphic

    6,484 followers

    We're so excited to bring on Robyn Macrae as a Tech Translator at Every Cure!

    View profile for Robyn Macrae, graphic

    AI Drug Repurposing | Ex-McKinsey | Life Science PhD

    Thrilled to be taking on a new position as Tech Translator at Every Cure, joining the team working to unlock the full potential of existing medicines to treat every disease and every patient they possibly can. The mission of the company is something I'm extremely passionate about and I'm excited to bring my pharmacology knowledge to help drive this impactful venture forward!

    • No alternative text description for this image
  • Every Cure reposted this

    View profile for David Fajgenbaum, MD, MBA, MSc, graphic

    Physician-Scientist @ UPenn | National Bestselling Author, Chasing My Cure | Co-Founder @ Every Cure & CDCN

    Novel drug development often feels like starting at your own 1-yard line, facing a daunting 99-yard drive with only a 10% chance of reaching the end zone. The journey is long and expensive, requiring years of research, clinical trials, and regulatory hurdles before even beginning to make an impact. The odds are stacked against us, and many promising drugs never reach their potential. 
In contrast, repurposing existing drugs is like beginning on the opponent's 5-yard line—much closer to making a meaningful difference. The drug is already developed, its safety profile is well established, and it’s ready to be tested in new ways.
 While repurposing may not yield the same financial rewards as developing a new blockbuster drug, it offers the potential to change lives more quickly than traditional pathways, leveraging existing knowledge and data to deliver effective therapies when they are needed most. At Every Cure, we are committed to seizing these opportunities and ensuring that no patient is ever told, “We’ve tried everything,” when a lifesaving cure may be sitting on the pharmacy shelf.
 Join us in our mission to unlock the potential of existing medications for all patients! #drugdevelopment #drugsaftey #drugdiscovery #pharma

  • Every Cure reposted this

    View profile for David Fajgenbaum, MD, MBA, MSc, graphic

    Physician-Scientist @ UPenn | National Bestselling Author, Chasing My Cure | Co-Founder @ Every Cure & CDCN

    Interesting results suggesting that GLP-1s may be able to reduce mortality across a number of different diseases including as many as 10 different cancers… wow! We love repurposing drugs for additional diseases they can treat… Lots of additional work is needed including rigorous RCTs, but certainly early data suggest that GLP-1s may be effective at reducing risk of multiple conditions (likely due to weight reduction and potentially weight-independent mechanisms). Every Cure #ChasingMyCure

    View profile for Eric Topol, MD, graphic

    Physician-Scientist, Author, Editor

    A 5-year observational study of ~12,000 individuals with obesity (without diabetes) taking GLP-1 drugs vs propensity-matched controls A significant reduction of all-cause mortality (HR 0.23, 95% CI 0.15, 0.34) and many other adverse outcomes https://lnkd.in/gisQN9CU

    • No alternative text description for this image
  • View organization page for Every Cure, graphic

    6,484 followers

    Today we are excited to feature our Head of Data Science, Lee Lancashire, PhD! Lee’s draw to Every Cure is personal as his son was diagnosed with a rare skin condition called Ichthyosis, which does not have an approved treatment. Dr. Lee Lancashire brings over 20 years of expertise in machine learning and statistics to his position as Head of Data Science at Every Cure. Specializing in the development of artificial neural network methodologies, his PhD research pioneered the application of neural nets to large-scale bioinformatics datasets. Before joining Every Cure, Lee served in a senior leadership capacity as Chief Information Officer, and later as Chief Data and AI Officer at Cohen Veterans Bioscience, where he led the strategy direction on numerous initiatives, developing innovative multi-modal systems modelingmodelling techniques for biomarker and drug target discovery using advanced AI. In addition to his professional pursuits, Lee dedicates time to volunteering as a trustee and as treasurer for the Ichthyosis Support Group, one of the largest charities supporting individuals and families with rare skin disorders.

  • Every Cure reposted this

    View profile for Grant W Mitchell, MD, MBA, graphic

    Co-Founder & CEO @ Every Cure

    A patient named Alan, was told, "we've tried everything, there's nothing more that we can do" and was preparing to go onto hospice care. This was before team members at Every Cure, Medidata Solutions and the Castleman Disease Collaborative Network, utilized AI to uncover a previously unknown use for the existing drug adalimumab, which ultimately saved his life. Alan has been in remission for over 19 months. We’re incredibly encouraged by the progress we’ve achieved to date and even more excited about the potential future impact as we integrate more data, optimize the algorithms, and investigate our most promising leads.  Our mission is to provide options for patients who have otherwise run out of hope by maximizing the potential of every drug to treat every disease it possibly can. This work is essential, and we are dedicated to making a meaningful impact. Thank you to Seema Kumar for the great question and Cure. for hosting this incredible event! Learn more about this story here: https://lnkd.in/e8FkS37q #drugdevelopment #pharma #ai #drugdiscovery #raredisease

  • Every Cure reposted this

    View profile for David Fajgenbaum, MD, MBA, MSc, graphic

    Physician-Scientist @ UPenn | National Bestselling Author, Chasing My Cure | Co-Founder @ Every Cure & CDCN

    When a drug receives FDA approval, its research and development (R&D) often shifts away from further exploration into areas such as new indications or formulation improvements. It's a common misconception that approval marks the peak of a drug's journey. In reality, it’s the opposite. When the drug eventually turns generic, it becomes more affordable and accessible than ever. Yet paradoxically, this is when R&D typically comes to a standstill. As someone whose life was saved by an old, generic drug, I am deeply invested in this topic. We should be maximizing these opportunities, not diminishing them. At Every Cure we are on a mission to shift the narrative and focus on how we can leverage these accessible drugs to their fullest potential. What are your thoughts on how we can reinvigorate R&D for generic drugs to enhance their impact and accessibility? #drugdevelopment #drugdiscovery #pharma #drugdelivery #repurposing

  • Every Cure reposted this

    View profile for David Fajgenbaum, MD, MBA, MSc, graphic

    Physician-Scientist @ UPenn | National Bestselling Author, Chasing My Cure | Co-Founder @ Every Cure & CDCN

    At 25 years old, my doctors didn’t think I was going to survive. They had run out of options for treating my rare and deadly disease. A priest even read me my last rites as my family said their final goodbyes. I somehow survived, thanks to a regimen of seven different chemotherapies, but I knew I would relapse again if I didn’t treat the underlying cause of my disease. I started running experiments on my cells and found that a communication line called mTOR was turned into overdrive. The best part was that there was already a drug made for a different disease that inhibited mTOR. I began taking that drug and have now been in remission for over 10 years! It begs the question: What other diseases could we find cures for if we maximized the uses of existing drugs? That’s why I co-founded @EveryCure, a non-profit that utilizes artificial intelligence to unlock the full potential of existing drugs! Go to EveryCure.org to join us on this mission! #medicine #raredisease #doctor

  • Every Cure reposted this

    View profile for David Fajgenbaum, MD, MBA, MSc, graphic

    Physician-Scientist @ UPenn | National Bestselling Author, Chasing My Cure | Co-Founder @ Every Cure & CDCN

    Ozempic and Wegovy stand out as compelling case studies in the repurposing of patented, profitable drugs. Their status encourages manufacturers to meet high demand, a dynamic that isn't always replicated in the realm of generic drugs, where profits may be marginal. The question then becomes, how do we incentivize generic manufacturers to scale up production when the margins are so thin? At Every Cure we are refining the landscape by matching the right drugs to the right patients and plan to work hand-in-hand with manufacturers to ensure those life-saving medications reach those who need them the most. I’d love to hear from you, what innovative strategies do you think could incentivize manufacturers to increase production of generic drugs? How can we all contribute to a healthcare system that not only discovers but also delivers these lifesaving treatments to those in need? #raredisease #pharma #drugdevelopment #drugdiscovery

  • Every Cure reposted this

    View profile for Grant W Mitchell, MD, MBA, graphic

    Co-Founder & CEO @ Every Cure

    Every Cure aims to build the world's best AI drug repurposing platform. In order to achieve this ambitious goal, it's critical to have the best datasets. To gather this high-quality data, we recognize the importance of collaboration and openness. That’s why we’re a nonprofit- to help create a neutral space where individuals and organizations feel secure in sharing their data. Collaborative efforts in data sharing can lead to improved models and insights that benefit all parties involved. Focusing on diseases that are often overlooked by the pharmaceutical industry, especially those affecting underserved populations, can lead to significant advancements in public health. With this structure and strategy, we're addressing critical gaps and working towards making a significant impact in the lives of patients with limited or no treatment options. If you work in the healthcare field and would like to donate data towards our mission please reach out to us at [email protected] #DrugRepurposing #AIInnovation #Biotech #Pharma #RareDisease

Similar pages

Funding